Access cutting-edge rectal cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access rectal cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related rectal cancer treatment provided free
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.
Sponsor: Weill Medical College of Cornell University
Check if you qualify for this rectal cancer clinical trial in New York, NY
If you're searching for rectal cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced rectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.